RU2014113967A - Комбинированная терапия рассеянного склероза интерфероном и андрографолидами - Google Patents
Комбинированная терапия рассеянного склероза интерфероном и андрографолидами Download PDFInfo
- Publication number
- RU2014113967A RU2014113967A RU2014113967A RU2014113967A RU2014113967A RU 2014113967 A RU2014113967 A RU 2014113967A RU 2014113967 A RU2014113967 A RU 2014113967A RU 2014113967 A RU2014113967 A RU 2014113967A RU 2014113967 A RU2014113967 A RU 2014113967A
- Authority
- RU
- Russia
- Prior art keywords
- series consisting
- interferon
- enyl
- formula
- compound
- Prior art date
Links
- 102000014150 Interferons Human genes 0.000 title claims abstract 20
- 108010050904 Interferons Proteins 0.000 title claims abstract 20
- 229940079322 interferon Drugs 0.000 title claims abstract 20
- 201000006417 multiple sclerosis Diseases 0.000 title claims abstract 4
- 238000002648 combination therapy Methods 0.000 title 1
- 238000000034 method Methods 0.000 claims abstract 24
- 150000001875 compounds Chemical class 0.000 claims abstract 13
- 229910052739 hydrogen Inorganic materials 0.000 claims abstract 11
- 239000001257 hydrogen Substances 0.000 claims abstract 11
- 208000016192 Demyelinating disease Diseases 0.000 claims abstract 10
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims abstract 10
- -1 3- (3-furanyl) propyl Chemical group 0.000 claims abstract 8
- 239000003814 drug Substances 0.000 claims abstract 7
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 claims abstract 6
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims abstract 6
- 125000003682 3-furyl group Chemical group O1C([H])=C([*])C([H])=C1[H] 0.000 claims abstract 5
- 150000002431 hydrogen Chemical class 0.000 claims abstract 5
- 229940079593 drug Drugs 0.000 claims abstract 4
- 102000003996 Interferon-beta Human genes 0.000 claims abstract 3
- 108090000467 Interferon-beta Proteins 0.000 claims abstract 3
- 125000000217 alkyl group Chemical group 0.000 claims abstract 3
- 125000000837 carbohydrate group Chemical group 0.000 claims abstract 3
- 229910052799 carbon Inorganic materials 0.000 claims abstract 3
- 150000002148 esters Chemical class 0.000 claims abstract 3
- 125000002768 hydroxyalkyl group Chemical group 0.000 claims abstract 3
- 229960001388 interferon-beta Drugs 0.000 claims abstract 3
- 150000003839 salts Chemical class 0.000 claims abstract 3
- 125000002791 glucosyl group Chemical group C1([C@H](O)[C@@H](O)[C@H](O)[C@H](O1)CO)* 0.000 claims abstract 2
- 125000004029 hydroxymethyl group Chemical group [H]OC([H])([H])* 0.000 claims abstract 2
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims abstract 2
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 claims abstract 2
- WKKBRRFSRMDTJB-UHFFFAOYSA-N Andrograpanin Chemical compound C=C1CCC2C(C)(CO)CCCC2(C)C1CCC1=CCOC1=O WKKBRRFSRMDTJB-UHFFFAOYSA-N 0.000 claims 3
- WKKBRRFSRMDTJB-JYBIWHBTSA-N Andrograpanin Natural products C([C@H]1[C@]2(C)CCC[C@]([C@H]2CCC1=C)(CO)C)CC1=CCOC1=O WKKBRRFSRMDTJB-JYBIWHBTSA-N 0.000 claims 3
- ASLUCFFROXVMFL-UHFFFAOYSA-N andrographolide Natural products CC1(CO)C(O)CCC2(C)C(CC=C3/C(O)OCC3=O)C(=C)CCC12 ASLUCFFROXVMFL-UHFFFAOYSA-N 0.000 claims 3
- BOJKULTULYSRAS-OTESTREVSA-N Andrographolide Chemical compound C([C@H]1[C@]2(C)CC[C@@H](O)[C@]([C@H]2CCC1=C)(CO)C)\C=C1/[C@H](O)COC1=O BOJKULTULYSRAS-OTESTREVSA-N 0.000 claims 2
- 230000037396 body weight Effects 0.000 claims 2
- BOJKULTULYSRAS-QPSYGYIJSA-N (3z,4s)-3-[2-[(1r,4as,5r,6r,8as)-6-hydroxy-5-(hydroxymethyl)-5,8a-dimethyl-2-methylidene-3,4,4a,6,7,8-hexahydro-1h-naphthalen-1-yl]ethylidene]-4-hydroxyoxolan-2-one Chemical compound C([C@H]1[C@]2(C)CC[C@@H](O)[C@]([C@H]2CCC1=C)(CO)C)\C=C1\[C@H](O)COC1=O BOJKULTULYSRAS-QPSYGYIJSA-N 0.000 claims 1
- BNLCOXWUZAOLDT-UHFFFAOYSA-N 14-deoxy-11-hydroxyandrographolide Natural products OCC1(C)C(O)CCC2(C)C1CCC(=C)C2C(O)CC1=CCOC1=O BNLCOXWUZAOLDT-UHFFFAOYSA-N 0.000 claims 1
- XBINLYXLOLWNSB-UHFFFAOYSA-N 14-deoxy-11-oxoandrographolide Natural products CC1(CO)C(O)CCC2(C)C1CCC(=C)C2C(=O)CC3=CC(=O)OC3 XBINLYXLOLWNSB-UHFFFAOYSA-N 0.000 claims 1
- SJKRRZPXYGTAGA-UHFFFAOYSA-N 14-deoxy-12-methoxyandrographolide Natural products C=C1CCC2C(C)(CO)C(O)CCC2(C)C1CC(OC)C1=CCOC1=O SJKRRZPXYGTAGA-UHFFFAOYSA-N 0.000 claims 1
- KHQNSSJNIXVKMK-UHFFFAOYSA-N 14-deoxy-12R-hydroxyandrographolide Natural products C=C1CCC2C(C)(CO)C(O)CCC2(C)C1CC(O)C1=CCOC1=O KHQNSSJNIXVKMK-UHFFFAOYSA-N 0.000 claims 1
- LMOGEODVJJLYGW-UHFFFAOYSA-N 14-deoxy-17beta-hydroxyandrographolide Natural products OCC1CCC2C(C)(CO)C(O)CCC2(C)C1CCC1=CCOC1=O LMOGEODVJJLYGW-UHFFFAOYSA-N 0.000 claims 1
- GVRNTWSGBWPJGS-DSJDWBEOSA-N 14-deoxyandrographolide Natural products O=C1C(CC[C@@H]2C(=C)CC[C@@H]3[C@@](CO)(C)[C@H](O)CC[C@]23C)=CCO1 GVRNTWSGBWPJGS-DSJDWBEOSA-N 0.000 claims 1
- KHQNSSJNIXVKMK-UQZPWQSVSA-N 4-[(1r)-2-[(1r,4as,5r,6r,8as)-6-hydroxy-5-(hydroxymethyl)-5,8a-dimethyl-2-methylidene-3,4,4a,6,7,8-hexahydro-1h-naphthalen-1-yl]-1-hydroxyethyl]-2h-furan-5-one Chemical compound C1([C@H](O)C[C@H]2[C@]3(C)CC[C@@H](O)[C@]([C@H]3CCC2=C)(CO)C)=CCOC1=O KHQNSSJNIXVKMK-UQZPWQSVSA-N 0.000 claims 1
- WQHWOZANSOUSAY-LZBAHHAZSA-N 4-[(e)-2-[(1r,4as,5r,6r,8ar)-6-hydroxy-5-(hydroxymethyl)-5,8a-dimethyl-2-methylidene-3,4,4a,6,7,8-hexahydro-1h-naphthalen-1-yl]ethenyl]-2-[2-[(1r,4as,5r,6r,8ar)-6-hydroxy-5-(hydroxymethyl)-5,8a-dimethyl-2-methylidene-3,4,4a,6,7,8-hexahydro-1h-naphthalen-1 Chemical compound C([C@H]1[C@]2(C)CC[C@@H](O)[C@]([C@H]2CCC1=C)(CO)C)C(C1C=C(\C=C\[C@H]2[C@@]3(CC[C@@H](O)[C@@](C)(CO)[C@H]3CCC2=C)C)C(=O)O1)C1=CCOC1=O WQHWOZANSOUSAY-LZBAHHAZSA-N 0.000 claims 1
- LMOGEODVJJLYGW-UQZPWQSVSA-N 4-[2-[(1r,2s,4as,5r,6r,8as)-6-hydroxy-2,5-bis(hydroxymethyl)-5,8a-dimethyl-1,2,3,4,4a,6,7,8-octahydronaphthalen-1-yl]ethyl]-2h-furan-5-one Chemical compound C([C@H]1[C@]2(C)CC[C@@H](O)[C@]([C@H]2CC[C@@H]1CO)(CO)C)CC1=CCOC1=O LMOGEODVJJLYGW-UQZPWQSVSA-N 0.000 claims 1
- WZHWNAKOQGIEEB-NDLGOLERSA-N 4-[2-[(1r,4as,5r,6r,8ar)-6-hydroxy-5-(hydroxymethyl)-5,8a-dimethyl-2-methylidene-3,4,4a,6,7,8-hexahydro-1h-naphthalen-1-yl]-2-oxoethyl]-2h-furan-5-one Chemical compound O=C([C@@H]1C(=C)CC[C@H]2[C@@]1(C)CC[C@@H](O)[C@]2(CO)C)CC1=CCOC1=O WZHWNAKOQGIEEB-NDLGOLERSA-N 0.000 claims 1
- GVRNTWSGBWPJGS-YSDSKTICSA-N 4-[2-[(1r,4as,5r,6r,8as)-6-hydroxy-5-(hydroxymethyl)-5,8a-dimethyl-2-methylidene-3,4,4a,6,7,8-hexahydro-1h-naphthalen-1-yl]ethyl]-2h-furan-5-one Chemical compound C([C@H]1[C@]2(C)CC[C@@H](O)[C@]([C@H]2CCC1=C)(CO)C)CC1=CCOC1=O GVRNTWSGBWPJGS-YSDSKTICSA-N 0.000 claims 1
- YGCYRQKJYWQXHG-RDNQFMDVSA-N 4-[2-[(1r,4as,5r,8as)-5,8a-dimethyl-2-methylidene-5-[[(2r,3r,4s,5s,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxymethyl]-3,4,4a,6,7,8-hexahydro-1h-naphthalen-1-yl]ethyl]-2h-furan-5-one Chemical compound C([C@@]1(C)[C@H]2CCC(=C)[C@@H](CCC=3C(OCC=3)=O)[C@]2(C)CCC1)O[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O YGCYRQKJYWQXHG-RDNQFMDVSA-N 0.000 claims 1
- YQZCSRAURNLCEK-WZLKLWACSA-N 4-[2-[(1s,2r,4as,5r,6r,8ar)-6-hydroxy-5-(hydroxymethyl)-5,8a-dimethylspiro[3,4,4a,6,7,8-hexahydro-1h-naphthalene-2,2'-oxirane]-1-yl]ethyl]-2h-furan-5-one Chemical compound C([C@H]1[C@]2(C)CC[C@@H](O)[C@]([C@H]2CC[C@@]11OC1)(CO)C)CC1=CCOC1=O YQZCSRAURNLCEK-WZLKLWACSA-N 0.000 claims 1
- YQZCSRAURNLCEK-UHFFFAOYSA-N 8,17-epoxy-14-deoxyandrographolide Natural products C1OC21CCC1C(C)(CO)C(O)CCC1(C)C2CCC1=CCOC1=O YQZCSRAURNLCEK-UHFFFAOYSA-N 0.000 claims 1
- BOJKULTULYSRAS-BEUDANMRSA-N Andropanolide Natural products O=C1/C(=C/C[C@@H]2C(=C)CC[C@@H]3[C@@](CO)(C)[C@H](O)CC[C@]23C)/[C@H](O)CO1 BOJKULTULYSRAS-BEUDANMRSA-N 0.000 claims 1
- WQHWOZANSOUSAY-UHFFFAOYSA-N Bisandrographolide A Natural products C=C1CCC2C(C)(CO)C(O)CCC2(C)C1CC(C1C=C(C=CC2C3(CCC(O)C(C)(CO)C3CCC2=C)C)C(=O)O1)C1=CCOC1=O WQHWOZANSOUSAY-UHFFFAOYSA-N 0.000 claims 1
- 206010061218 Inflammation Diseases 0.000 claims 1
- 125000004432 carbon atom Chemical group C* 0.000 claims 1
- MEEPUSVTMHGIPC-UHFFFAOYSA-N deoxyandrographiside Natural products OC1CCC2(C)C(CCC=3C(OCC=3)=O)C(=C)CCC2C1(C)COC1OC(CO)C(O)C(O)C1O MEEPUSVTMHGIPC-UHFFFAOYSA-N 0.000 claims 1
- GVRNTWSGBWPJGS-UHFFFAOYSA-N deoxyandrographolide Natural products C=C1CCC2C(C)(CO)C(O)CCC2(C)C1CCC1=CCOC1=O GVRNTWSGBWPJGS-UHFFFAOYSA-N 0.000 claims 1
- 239000000539 dimer Substances 0.000 claims 1
- 239000002552 dosage form Substances 0.000 claims 1
- 230000004054 inflammatory process Effects 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- GRVDJDISBSALJP-UHFFFAOYSA-N methyloxidanyl Chemical group [O]C GRVDJDISBSALJP-UHFFFAOYSA-N 0.000 claims 1
- 239000000178 monomer Substances 0.000 claims 1
- BBGWVUQBIGGVLS-UHFFFAOYSA-N neoandrographolide Natural products CC1(COC2OC(CO)C(O)C(O)C2O)C(O)CCC3(C)C(CCC4=C(O)COC4=O)C(=C)CCC13 BBGWVUQBIGGVLS-UHFFFAOYSA-N 0.000 claims 1
- YGCYRQKJYWQXHG-UHFFFAOYSA-N neoandrographoside Natural products C1CCC2(C)C(CCC=3C(OCC=3)=O)C(=C)CCC2C1(C)COC1OC(CO)C(O)C(O)C1O YGCYRQKJYWQXHG-UHFFFAOYSA-N 0.000 claims 1
- UUEVFMOUBSLVJW-UHFFFAOYSA-N oxo-[[1-[2-[2-[2-[4-(oxoazaniumylmethylidene)pyridin-1-yl]ethoxy]ethoxy]ethyl]pyridin-4-ylidene]methyl]azanium;dibromide Chemical compound [Br-].[Br-].C1=CC(=C[NH+]=O)C=CN1CCOCCOCCN1C=CC(=C[NH+]=O)C=C1 UUEVFMOUBSLVJW-UHFFFAOYSA-N 0.000 claims 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
- A61K31/341—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide not condensed with another ring, e.g. ranitidine, furosemide, bufetolol, muscarine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/21—Interferons [IFN]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/21—Interferons [IFN]
- A61K38/215—IFN-beta
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Immunology (AREA)
- Neurology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201161578650P | 2011-12-21 | 2011-12-21 | |
| US61/578,650 | 2011-12-21 | ||
| PCT/US2012/070568 WO2013096423A1 (en) | 2011-12-21 | 2012-12-19 | Combination therapy with interferon and andrographolides for multiple sclerosis |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| RU2014113967A true RU2014113967A (ru) | 2016-02-10 |
Family
ID=48669439
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2014113967A RU2014113967A (ru) | 2011-12-21 | 2012-12-19 | Комбинированная терапия рассеянного склероза интерфероном и андрографолидами |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US9060994B2 (enExample) |
| EP (1) | EP2670406B1 (enExample) |
| JP (1) | JP5936707B2 (enExample) |
| AU (1) | AU2012359081B2 (enExample) |
| BR (1) | BR112014015178A2 (enExample) |
| CA (1) | CA2853779C (enExample) |
| CL (1) | CL2014001663A1 (enExample) |
| ES (1) | ES2554459T3 (enExample) |
| RU (1) | RU2014113967A (enExample) |
| WO (1) | WO2013096423A1 (enExample) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN109562097B (zh) * | 2016-06-08 | 2022-06-07 | 因诺生物科学有限责任公司 | 穿心莲内酯治疗多发性硬化的进行形式 |
| US11318153B2 (en) | 2018-06-25 | 2022-05-03 | Bialpha International Sdn. Bhd. | Method of using Neoandrographolide for lowering blood sugar, lowering blood lipid, improving liver function and improving renal function |
| CN109824655B (zh) * | 2019-04-08 | 2021-09-24 | 沈阳药科大学 | 穿心莲内酯化合物及其制备方法和用途 |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1043027A1 (en) * | 1999-04-08 | 2000-10-11 | Applied Research Systems ARS Holding N.V. | Treatment of multiple sclerosis with a combination of Interferon and Growth hormone |
| US6410590B1 (en) | 2000-02-03 | 2002-06-25 | Dr. Reddy's Research Foundation | Compounds having antitumor activity: process for their preparation and pharmaceutical compositions containing them |
| US20050181033A1 (en) | 2000-06-29 | 2005-08-18 | Dekker John P.Iii | Method for delivering interferons to the intradermal compartment |
| CA2463935A1 (en) | 2001-09-18 | 2003-03-27 | Chiron Corporation | Methods for treating multiple sclerosis |
| AU2004315105A1 (en) * | 2004-02-03 | 2005-08-18 | Universidad Austral De Chile | Composition of labdane diterpenes extracted from Andrographis paniculata, useful for the treatment of autoimmune diseases, and Alzheimer disease by activation of PPR-gamma receptors |
| US20050220764A1 (en) | 2004-04-01 | 2005-10-06 | Schering Aktiengesellschaft | Higher-doses of interferon-beta for treatment of multiple sclerosis |
| US20080108641A1 (en) | 2006-02-08 | 2008-05-08 | Ajami Alfred M | Compounds for treating inflammatory disorders, demyelinating disdorders and cancers |
| AU2010270971B2 (en) * | 2009-06-22 | 2015-08-20 | Sk Biopharmaceuticals Co., Ltd. | Methods for treating or preventing fatigue |
-
2012
- 2012-12-19 AU AU2012359081A patent/AU2012359081B2/en active Active
- 2012-12-19 BR BR112014015178A patent/BR112014015178A2/pt not_active Application Discontinuation
- 2012-12-19 US US13/984,124 patent/US9060994B2/en active Active
- 2012-12-19 JP JP2014548825A patent/JP5936707B2/ja active Active
- 2012-12-19 ES ES12859754.9T patent/ES2554459T3/es active Active
- 2012-12-19 RU RU2014113967A patent/RU2014113967A/ru not_active Application Discontinuation
- 2012-12-19 EP EP12859754.9A patent/EP2670406B1/en active Active
- 2012-12-19 CA CA2853779A patent/CA2853779C/en active Active
- 2012-12-19 WO PCT/US2012/070568 patent/WO2013096423A1/en not_active Ceased
-
2014
- 2014-06-20 CL CL2014001663A patent/CL2014001663A1/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| WO2013096423A1 (en) | 2013-06-27 |
| CA2853779C (en) | 2016-04-26 |
| JP2015500880A (ja) | 2015-01-08 |
| US9060994B2 (en) | 2015-06-23 |
| CA2853779A1 (en) | 2013-06-27 |
| US20140301981A1 (en) | 2014-10-09 |
| JP5936707B2 (ja) | 2016-06-22 |
| EP2670406B1 (en) | 2015-09-02 |
| ES2554459T3 (es) | 2015-12-21 |
| EP2670406A4 (en) | 2014-05-28 |
| NZ625051A (en) | 2016-07-29 |
| AU2012359081B2 (en) | 2015-09-17 |
| EP2670406A1 (en) | 2013-12-11 |
| AU2012359081A1 (en) | 2014-06-05 |
| BR112014015178A2 (pt) | 2017-06-13 |
| CL2014001663A1 (es) | 2015-02-27 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| RU2010121827A (ru) | Композиции для лечения болезни паркинсона | |
| UA107578C2 (uk) | Комбінована терапія при лікуванні діабету | |
| EA201171376A1 (ru) | Производные тиено[2,3-b]пиридина в качестве ингибиторов репликации вируса | |
| JP2013545730A5 (enExample) | ||
| NZ587202A (en) | Methods for measuring a patient response upon administration of a drug and compositions thereof | |
| RU2014102924A (ru) | Композиция для контролируемой стимуляции яичников | |
| EA201492010A1 (ru) | Применение высокой дозы лахинимода для лечения рассеянного склероза | |
| HRP20192189T1 (hr) | Doziranja i terapijske primjene l-4-klorokinurenina | |
| RU2013127420A (ru) | Способы уменьшения психогенного или компульсивного переедания | |
| RU2011128335A (ru) | Альфа-производные цис-мононенасыщенных жирных кислот, предназначенные для применения в качестве лекарственного средства | |
| NZ598465A (en) | Dosage regimens for hcv combination therapy comprising bi201335, interferon alpha and ribavirin | |
| JP2011512399A (ja) | 卵巣癌を治療するための、パクリタキセルを含む配合剤 | |
| JP2016505050A5 (enExample) | ||
| JP2022519007A5 (enExample) | ||
| MX2026002937A (es) | Nuevas fenilalquilaminas y su uso en el tratamiento de trastornos psiquiatricos | |
| RU2012108144A (ru) | Противораковая терапия, направленная против раковых стволовых клеток и форм рака, устойчивых к лечению лекарственными препаратами | |
| NZ587941A (en) | Methods to inhibit tumor cell growth by using lansoprazole | |
| JP2015500880A5 (enExample) | ||
| CA2516458A1 (en) | Use of kahalalide compounds for the manufacture of a medicament for the treatment of psoriasis | |
| FI3654989T3 (fi) | Kladribiinin käyttö neuromuskulaarisen autoimmuunisairauden hoitoon | |
| MX2010006310A (es) | O-desmetil-venlafaxina para el tratamiento de transtorno depresivo mayor. | |
| JP2013503908A5 (enExample) | ||
| NZ597675A (en) | Medicament for the long term nsaid use | |
| RU2012114097A (ru) | Терапевтический агент против хронической боли | |
| US10702534B2 (en) | Compositions and methods relating to the radioprotective effects of apilimod |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FA92 | Acknowledgement of application withdrawn (lack of supplementary materials submitted) |
Effective date: 20170131 |